1. Home
  2. BFS vs VIR Comparison

BFS vs VIR Comparison

Compare BFS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BFS

Saul Centers Inc.

HOLD

Current Price

$32.36

Market Cap

793.2M

Sector

Real Estate

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$8.43

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFS
VIR
Founded
1993
2016
Country
United States
United States
Employees
98
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
793.2M
1.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BFS
VIR
Price
$32.36
$8.43
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$19.63
AVG Volume (30 Days)
47.5K
3.5M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
7.22%
N/A
EPS Growth
N/A
17.49
EPS
N/A
N/A
Revenue
N/A
$68,556,000.00
Revenue This Year
$6.07
N/A
Revenue Next Year
$7.05
$1,049.62
P/E Ratio
$30.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.16
$4.16
52 Week High
$36.51
$10.91

Technical Indicators

Market Signals
Indicator
BFS
VIR
Relative Strength Index (RSI) 37.14 45.05
Support Level $31.06 $5.14
Resistance Level $32.43 $10.29
Average True Range (ATR) 0.67 0.47
MACD -0.15 -0.18
Stochastic Oscillator 7.81 3.20

Price Performance

Historical Comparison
BFS
VIR

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: